Barrow Hanley Mewhinney & Strauss LLC acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 837,530 shares of the company's stock, valued at approximately $69,892,000. Barrow Hanley Mewhinney & Strauss LLC owned approximately 2.41% of TransMedics Group at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in TMDX. Braidwell LP increased its holdings in shares of TransMedics Group by 85.1% during the 2nd quarter. Braidwell LP now owns 609,715 shares of the company's stock worth $40,497,000 after purchasing an additional 280,324 shares during the period. Deutsche Bank AG bought a new position in TransMedics Group in the second quarter worth $14,415,000. Bank of New York Mellon Corp acquired a new stake in TransMedics Group during the second quarter worth $12,869,000. Trek Financial LLC acquired a new stake in TransMedics Group during the third quarter worth $11,989,000. Finally, Legal & General Group Plc bought a new position in shares of TransMedics Group during the 2nd quarter worth about $5,286,000. Institutional investors and hedge funds own 99.67% of the company's stock.
TransMedics Group Price Performance
Shares of TMDX stock opened at $85.25 on Friday. TransMedics Group, Inc. has a 12-month low of $60.10 and a 12-month high of $156.00. The firm has a market capitalization of $2.96 billion, a price-to-earnings ratio of 23.10, a price-to-earnings-growth ratio of 1.64 and a beta of 2.14. The company has a quick ratio of 4.15, a current ratio of 4.53 and a debt-to-equity ratio of 1.46. The firm has a fifty day moving average of $80.88 and a 200-day moving average of $90.94.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.21. The company had revenue of $203.01 million during the quarter, compared to the consensus estimate of $178.06 million. TransMedics Group had a return on equity of 13.30% and a net margin of 19.85%. The company's revenue for the quarter was up 41.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.66 earnings per share. On average, equities research analysts forecast that TransMedics Group, Inc. will post 1.66 earnings per share for the current year.
Insider Activity at TransMedics Group
In related news, Director David Weill bought 1,336 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were acquired at an average price of $81.63 per share, with a total value of $109,057.68. Following the completion of the transaction, the director owned 16,392 shares in the company, valued at $1,338,078.96. The trade was a 8.87% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 6.90% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
Several equities research analysts have recently commented on TMDX shares. Stifel Nicolaus boosted their target price on shares of TransMedics Group from $70.00 to $80.00 and gave the company a "hold" rating in a research note on Friday. TD Cowen reiterated a "buy" rating and set a $120.00 target price on shares of TransMedics Group in a research report on Tuesday, September 8th. Needham & Company LLC lifted their price target on shares of TransMedics Group from $106.00 to $110.00 and gave the company a "buy" rating in a report on Friday, November 6th. Canaccord Genuity Group boosted their price target on shares of TransMedics Group from $95.00 to $120.00 and gave the company a "buy" rating in a research report on Friday, November 6th. Finally, Wall Street Zen raised shares of TransMedics Group from a "sell" rating to a "hold" rating in a research note on Saturday, November 7th. Five analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $113.30.
Check Out Our Latest Research Report on TMDX
TransMedics Group Profile
(
Free Report)
TransMedics Group, Inc. is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services. The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TransMedics Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.
While TransMedics Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.